Compare Cytokinetics Inc (CYTK) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Indonesia Energy Corporation Limited — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Indonesia Energy Corporation Limited trades at $2.85 (market cap $42.62M). The key difference: Cytokinetics Inc is far larger — about 199.4× Indonesia Energy Corporation Limited's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Indonesia Energy Corporation Limited for 24 Days on average.
| CYTK | INDO | |
|---|---|---|
Market Cap | $8.50B | $42.62M |
Volume | 2,395,556 | 60,371 |
Sector | Health | Energy |
52-Week High | $87.26 | $6.74 |
52-Week Low | $54.76 | $2.49 |
Typical Hold Time | 19 Days | 24 Days |
Enterprise Value | $8.60B | $37.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
INDO trades at $2.77 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $5.10 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from analysts, fundamental weaknesses and negative earnings trends pose significant risks. The stock's outlook depends on successful execution of drilling operations to improve financial performance. Investors should weigh high operational risks against potential growth from new production.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
